Research programme: NK cell therapies - Wugen
Latest Information Update: 04 Mar 2021
At a glance
- Originator WUGEN
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Acute myeloid leukaemia; Multiple myeloma